Coya Therapeutics, Inc.
COYA
$5.26
$0.040.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.55M | 9.55M | 9.55M | 6.13M | 6.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.55M | 9.55M | 9.55M | 6.13M | 6.00M |
| Cost of Revenue | 11.87M | 11.54M | 10.91M | 7.41M | 5.50M |
| Gross Profit | -8.31M | -1.98M | -1.35M | -1.28M | 500.70K |
| SG&A Expenses | 8.89M | 9.13M | 8.87M | 8.61M | 7.83M |
| Depreciation & Amortization | 27.20K | 27.20K | 27.20K | 27.20K | 27.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.78M | 20.69M | 19.80M | 16.05M | 13.36M |
| Operating Income | -17.22M | -11.14M | -10.25M | -9.92M | -7.36M |
| Income Before Tax | -15.60M | -9.98M | -9.38M | -9.58M | -7.26M |
| Income Tax Expenses | -720.30K | 723.90K | 723.90K | 723.90K | 723.90K |
| Earnings from Continuing Operations | -14.88 | -10.70 | -10.10 | -10.30 | -7.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.88M | -10.70M | -10.10M | -10.30M | -7.99M |
| EBIT | -17.22M | -11.14M | -10.25M | -9.92M | -7.36M |
| EBITDA | -17.20M | -11.11M | -10.22M | -9.89M | -7.33M |
| EPS Basic | -0.99 | -0.69 | -0.77 | -0.89 | -0.82 |
| Normalized Basic EPS | -0.64 | -0.38 | -0.43 | -0.48 | -0.44 |
| EPS Diluted | -0.99 | -0.69 | -0.77 | -0.89 | -0.82 |
| Normalized Diluted EPS | -0.64 | -0.38 | -0.43 | -0.48 | -0.44 |
| Average Basic Shares Outstanding | 60.95M | 55.63M | 50.36M | 45.39M | 40.65M |
| Average Diluted Shares Outstanding | 60.95M | 55.63M | 50.36M | 45.39M | 40.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |